Home › Updated Findings from KEYNOTE-012 for KEYTRUDA (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer
 

Keywords :   


Updated Findings from KEYNOTE-012 for KEYTRUDA (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer

2016-06-06 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data with KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy from two studies (KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Data are being presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: or with show updated

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.05P&G Patents Hair Conditioner with Antimicrobial System
03.05Post Offices expert gave false evidence to court
03.05Melting Massage Bar Patented by Johnson & Johnson
03.05How the computer games industry is embracing AI
03.05Apple sees biggest fall in sales for a year
02.05Turkey halts trade with Israel over Gaza 'tragedy'
02.05Loop Industries and Ester Ltd. Announce Joint Venture
02.05The Oldham Group names Hunter Collins account manager
More »